Document is current
Any future updates will be listed below
-
Authors
Guillen, Elena
Barry, Sean
Jost, Nils
Ekman, Niklas
Knippel, Verena
Kuhlmann-Gottke, Johanna
Maier, Julia
Weise, Martina
Laslop, Andrea
Anour, René
van Zandbergen, Ger
Kirsch‑Stefan, Nadine
-
Funding
Funding for this research was provided by:
Bundesministerium für Gesundheit (2522FSB450)
Paul-Ehrlich-Institut - Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel
- License Information
-
More Information
Article History
Accepted: 24 February 2025
First Online: 1 April 2025
Declarations
:
: EG, NK-S, SB, NJ, and NE wrote the first draft of the manuscript and VK, JK-G, JM, MW, AL, RA and GvZ commented and critically revised previous versions of the manuscript. EG performed the literature analysis and interpretation. NK-S conceived and designed the manuscript and supervised the process. All authors read and approved the final manuscript.
: Open Access funding enabled and organized by Projekt DEAL. This study was funded by the German Federal Ministry of Health based on a decision by the German Bundestag. The authors have no potential conflicts of interest or financial disclosures that are pertinent to this article. The views expressed in this article are the personal views of the authors and should not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agencies with which the authors are affiliated.
: This study was funded by the German Federal Ministry of Health based on a decision by the German Bundestag (Grant no. 2522FSB450).
: Not applicable.
: Not applicable.
: Not applicable.
: No data were used for the article.
: Not applicable.
